Multiple Myeloma in Mexico: A 20-year experience at a single institution

Ruíz‐Argüelles, Guillermo J.; Gómez-Rangel, J. David; Ruíz-Delgado, Guillermo J.; Aguilar-Romero, Leticia

doi:10.1016/j.arcmed.2003.09.013

Cited by 23 publications

(17 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 The prevalence of other monoclonal gammopathies in Mexico also has been found to be lower than that described in white Americans. Multiple myeloma is one-third to one-half as common, 5 whereas Waldenström macroglobulinemia is oneeleventh as common. 6 A genetic basis for these geographic differences is also suggested by similarities in certain features of hematologic diseases and their prevalence in Mexicans vs Asians.…”

Section: Genetic Predisposition For Monoclonal Gammopathy Of Undetermmentioning

confidence: 99%

Genetic Predisposition for Monoclonal Gammopathy of Undetermined Significance

Ruíz-Delgado¹,

Ruíz‐Argüelles

2008

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Section: Genetic Predisposition For Monoclonal Gammopathy Of Undetermmentioning

confidence: 99%

Genetic Predisposition for Monoclonal Gammopathy of Undetermined Significance

Ruíz-Delgado¹,

Ruíz‐Argüelles

2008

Mayo Clinic Proceedings

View full text Add to dashboard Cite

“…In general, there is a low prevalence of monoclonal gammopathy in Mexican mestizos compared to Caucasians [47]. In Mexico, the MM incidence represents 4.2% of hematologic malignancies, which is 2-3 times less frequent than in Caucasians [48]. A diminished lower prevalence has also been reported in other monoclonal gammopathies in Mexico, like WM, representing 4.3% of all the malignant monoclonal gammopathies and 0.18% of all hematological malignancies in Mexico, in contrast to 2% in the Caucasian population [14] (Fig.…”

Section: Malignant Monoclonal Gammopathiesmentioning

confidence: 99%

Geographic Hematology: Some Observations in Mexico

et al. 2018

View full text Add to dashboard Cite

In 1963 Jean Bernard introduced the concept of “geographic hematology” and distinguished 2 branches, i.e., “ethnic hematology,” which deals with differences between populations, and “environmental hematology,” which considers factors such as food habits, infections, and others. Both of these branches have implications in the distribution of hematological diseases worldwide. In comparison with Caucasian populations, in Mexico a significantly higher prevalence of acute lymphoblastic, acute promyelocytic, and acute megakaryoblastic leukemias has been described. The rate of chronic myeloid leukemia seems to be as high as that reported in Caucasian populations, while other myeloproliferative neoplasias are significantly less frequent in Mexico. Significantly lower prevalences of hairy cell leukemia, chronic lymphocytic leukemia, multiple myeloma, and Waldenström’s macroglobulinemia have been reported from Mexico. Regrettably, the influence of drug companies interested in selling their new and expensive drugs has resulted in both overdiagnosis of some diseases and overidentification of the refractory forms of some of these conditions to justify the use of unnecessary drugs.

show abstract

“…The diminished aggressiveness of CLL in México may stem from several facts: (a) Most patients (80%) presented in this study in early stages of the disease (Rai stages 0-2); (b) 89% of patients were ZAP-70 negative, whereas in Caucasians the negativity of ZAP-70 is around 60% [12]; (c) There were no cases of T-CLL; (d) Genetic factors may be involved as has been shown in multiple myeloma [4,[9][10][11], and (e) Other unknown reasons.…”

Section: Discussionmentioning

confidence: 63%

“…As far as the age of the patients is concerned, the median age was found to be lower than that informed in Caucasian populations (65 versus 70 years) [8]. We have previously shown that multiple myeloma, in addition to being less frequent in Mexican mestizos, is also less aggressive [9,10]. In this study, despite the use of medications that were not especially expensive, we observed good patient outcomes in patients with newly diagnosed CLL, with an OS of more than 20 years (median not yet reached): these data suggest that the clinical course of CLL patients in México is less aggressive than in Caucasian populations, as it has been shown in multiple myeloma [9][10][11].…”

Section: Discussionmentioning

confidence: 77%

“…We have previously shown that multiple myeloma, in addition to being less frequent in Mexican mestizos, is also less aggressive [9,10]. In this study, despite the use of medications that were not especially expensive, we observed good patient outcomes in patients with newly diagnosed CLL, with an OS of more than 20 years (median not yet reached): these data suggest that the clinical course of CLL patients in México is less aggressive than in Caucasian populations, as it has been shown in multiple myeloma [9][10][11]. Genetic differences have been suggested to explain the differences in the prevalence of CLL in México [4], but the precise explanation has not been found.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Up to half of patients diagnosed with chronic lymphocytic leukemia in México may not require treatment

et al. 2020

View full text Add to dashboard Cite

2020) Up to half of patients diagnosed with chronic lymphocytic leukemia in México may not require treatment, Hematology, 25:1, 156-159, ABSTRACT Introduction: Although therapeutic choices for patients with chronic lymphocytic leukemia (CLL) were once limited, treatment of this disease has vastly improved in the last decades. Patients and methods: Consecutive CLL patients diagnosed in a single institution were analyzed. Treatment was withheld in persons with CLL Rai stage 0 or 1, until progression and in persons with stages 2-4, with a negative expression of ZAP-70 until progression. Between 1983 and 1991, patients were give chlorambucil and prednisone (CP); after 1991 fludarabine and cyclophosphamide (FC) and after 1998, rituximab and FC (FCR). Results: 98 patients with CLL were identified; 49 were followed for >3 months. 21 persons (43%) did not require treatment nor progressed; 14 received CP, 6 FC, 7 FCR and one rituximab. Median overall survival (OS) has not been reached, being above 247 months; median OS for patients given CP was 115 months, for FC above 132 months and for FCR above 136 months (p > 0.5). Conclusion: CLL seems to be less aggressive in Mexican mestizos than in Caucasians; 43% of patients do not need treatment at all.

show abstract

Multiple Myeloma in Mexico: A 20-year experience at a single institution

Cited by 23 publications

References 10 publications

Genetic Predisposition for Monoclonal Gammopathy of Undetermined Significance

Genetic Predisposition for Monoclonal Gammopathy of Undetermined Significance

Geographic Hematology: Some Observations in Mexico

Up to half of patients diagnosed with chronic lymphocytic leukemia in México may not require treatment

Contact Info

Product

Resources

About